In a phase 2a study (NCT03256526), administration of Pfizer’s KHK inhibitor compound (PF06835919) at doses of 75 mg or 300 mg for 6 weeks was evaluated in subjects with non-alcoholic fatty liver disease (NAFLD) [35]. Here, KHK is linked to metabolic dysfunction-associated steatotic liver disease.